{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031355","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.826596+00:00","generated_at":"2026-06-21T23:13:05.916908+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Pharma Q3 2022 revenue $3.2M (+315% YoY); net loss narrows to $3.0M","bullets":["Product sales and royalties $3.2M, up 315% YoY and 37% sequentially, 7th straight sequential growth.","Net loss $3.0M ($0.12/share) vs $6.1M ($0.24/share) prior year; gross profit $2.0M vs $0.1M.","ALKINDI SPRINKLE sales grew 183% YoY and 19% QoQ; Carglumic Acid sales up 40% QoQ.","Acquired Betaine Anhydrous, a third FDA-approved rare disease product, expected accretive in 2023.","Zonisade FDA approval triggered $5M milestone payment, to be recognized in Q4 2022; cash $13.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031355","json":"https://secwatch.observer/filing/0001493152-22-031355.json","markdown":"https://secwatch.observer/filing/0001493152-22-031355.md","text":"https://secwatch.observer/filing/0001493152-22-031355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/0001493152-22-031355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:13:05.916908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8393ab4e1368b178cbf5d4a79e18db5181566803","claim":"Eton Pharmaceuticals, Inc. reported third quarter ended September 30, 2022 results: revenue $3.2 million, net income Net loss of $3.0 million or $0.12 per basic and diluted share, EPS $0.12 per basic and diluted share.","evidence_excerpt":"and Recent Business Highlights Reported seventh straight quarter of sequential growth in product sales and royalty revenue. Eton reported total third quarter 2022 revenue of $3.2 million, comprised entirely of product sales and royalty revenue, representing growth of 315% over the prior year and 37% over the second quarter of 2022. Continued strong growth in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/0001493152-22-031355-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.2 million"},{"label":"Net income","value":"Net loss of $3.0 million or $0.12 per basic and diluted share"},{"label":"EPS","value":"$0.12 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}